CAR-T 세포 치료 시장 규모, 점유율, 동향, 산업 분석 보고서 : 적응증별, 표적 항원별, 지역별 - 시장 예측(2025-2034년)

The global CAR-T cell therapy market size is expected to reach USD 188.84 billion by 2034, according to a new study by Polaris Market Research. The report "CAR-T Cell Therapy Market Size, Share, Trends, Industry Analysis Report: By Indication, Target Antigen [CD19/CD22, BCMA (B-Cell Maturation Antigen), and Others], and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Chimeric Antigen Receptor T-cell (CAR-T) therapy represents an advancement in cancer treatment, transforming immuno-oncology. The therapy offers personalized and highly effective treatment options for certain cancers, particularly hematological malignancies, by engineering a patient's T-cells to express synthetic receptors that target specific cancer antigens. The global CAR-T cell therapy market has witnessed exponential growth over the last decade, driven by rapid advancements in biotechnology, increasing approval rates of CAR-T therapies, and rising demand for innovative cancer treatments.

The increasing prevalence of cancer globally, coupled with a growing preference for precision medicine, has fueled demand for advanced treatment modalities such as CAR-T cell therapy. Moreover, supportive regulatory frameworks and rapid approval pathways have accelerated the availability of CAR-T therapies. Government and private investments in research further propel the CAR-T cell therapy market expansion.

The development of next-generation CAR-T therapies, including multi-target CAR-T cells and armored CAR-T cells, is driving the CAR-T cell therapy market growth. Multi-target CAR-T cells are engineered to recognize multiple antigens, addressing issues such as tumor heterogeneity and antigen escape, which limit the efficacy of traditional CAR-T treatments. Armored CAR-T cells are designed to overcome the immunosuppressive tumor microenvironment by secreting cytokines or other molecules to enhance anti-tumor activity.

The application of CAR-T therapy is expanding beyond oncology. Researchers are exploring its potential in treating autoimmune diseases such as lupus and multiple sclerosis and infectious diseases, including HIV. These novel applications are estimated to significantly broaden the market scope and impact.

CAR-T Cell Therapy Market Report Highlights

In terms of indication, the follicular lymphoma (FL) segment is expected to grow at the fastest pace, with a CAGR of 43.2% during the forecast period due to the rising incidence of refractory and high-risk cancer cases.

Based on target antigen, the CD19/CD22 antigen segment, valued at USD 6,258.5 billion in 2024, held the largest market share owing to its established role in treating B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).

In the global market, the North America CAR-T cell therapy market held a 47.16% market share in 2024 due to the presence of advanced healthcare infrastructure, significant research and development investments, and a high prevalence of hematologic malignancies.

The Europe CAR-T cell therapy market is expected to witness a CAGR of 33.2% during the forecast period due to increased focus on expanding access to advanced therapies, coupled with the rising prevalence of relapsed or refractory hematologic cancers.

A few of the global key market players are Bluebird Bio; Celgene Corporation; Gilead Sciences; Cellectis; Servier Laboratories; Pfizer Inc.; Merck; Amgen; Intellia Therapeutics; Novartis; Caribou Biosciences; Celyad; Bellicum Pharmaceuticals, Inc.; Noile-Immune Biotech; Nanjing Legend Biotechnology Co., Ltd.; Johnson & Johnson; and Sangamo Therapeutics, Inc.

Polaris Market Research has segmented the CAR-T cell therapy market report on the basis of indication, antigen, and region:

By Indication Outlook (Revenue, USD Billion, 2020-2034)

• DLBCL (Diffuse large B-cell lymphoma)
• ALL (Acute Lymphoblastic Leukemia)
• CLL (Chronic Lymphocytic Leukemia)
• MM (Multiple Myeloma)
• FL (Follicular Lymphoma)
• Mastozytosis
• Myeloid Fibrosis
• MLL (Mixed Lineage Leukemia)
• Thymic Cancer
• Glioblastoma
• AML (Acute Myeloid Leukemia)
• Other

By Target Antigen Outlook (Revenue, USD Billion, 2020-2034)

• CD19/CD22
• BCMA (B-Cell Maturation Antigen)
• Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

• North America
• US
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa
• Latin America
• Mexico
• Brazil
• Argentina
• Rest of Latin America

Table of Contents

Chapter 1. Introduction

• 1.1 Report Description
  • 1.1.1 Objectives of the Study
  • 1.1.2 Market Scope
• 1.2 Assumptions
• 1.3 Stakeholders
• 1.4 List of Abbreviations

Chapter 2. Executive Summary

• 2.1 Market Highlights

Chapter 3. Research Methodology

• 3.1 Overview
  • 3.1.1 Data Mining
• 3.2 Data Sources
  • 3.2.1 Primary Sources
  • 3.2.2 Secondary Sources

Chapter 4. CAR-T Cell Therapy Market Insights

• 4.1 CAR-T Cell Therapy Market Dynamics
  • 4.1.1 Drivers and Opportunities
    • 4.1.1.1 Promising growth in leukemia segment for DLBCL and Multiple Myeloma coupled with launches
    • 4.1.1.2 Potential applications in solid tumor
  • 4.1.2 Restraints and Challenges
    • 4.1.2.1 Patient Relapse
    • 4.1.2.2 Manufacturing and logistics challenges
    • 4.1.2.3 Economic model/reimbursement/scaling
• 4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers (High)
  • 4.2.2 Threats of New Entrants: (High)
  • 4.2.3 Bargaining Power of Buyers (Low)
  • 4.2.4 Threat of Substitute (Low)
  • 4.2.5 Rivalry among existing firms (High)
• 4.3 PEST Analysis
• 4.4 Timeline of CAR-T Cell Therapy Development
• 4.5 CAR-T Cell Manufacturing Outlook
• 4.6 Side-effects of CAR-T Cell
• 4.7 Antigens targeting solid tumors
• 4.8 Clinical trials Landscape for CAR-T
• 4.9 Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
• 4.10 New Innovations in CAR-T therapies
  • 4.10.1 "Off-the-shelf" CAR-T or allogenic CAR-T
  • 4.10.2 Development of Dual CAR-T
  • 4.10.3 Development of Non-viral transcription technologies
  • 4.10.4 The advent of TIL as well as TC R therapies
    • 4.10.4.1 TCR (T-cell receptor)
    • 4.10.4.2 TIL (Tumor-Infiltrating Lymphocytes)
• 4.11 CAR-T Cell Therapy Market - Covid Impact Analysis
• 4.12 Customization - CAR-T Cell Market

Chapter 5. CAR-T Cell Therapy Market Assessment by Indication

• 5.1 Introduction
• 5.2 DLBCL
• 5.3 ALL
• 5.4 CLL
• 5.5 MM
• 5.6 FL
• 5.7 Mastozytosis
• 5.8 Myeloid Fibrosis
• 5.9 MLL
• 5.10 Thymic Cancer
• 5.11 Glioblastoma
• 5.12 AML
• 5.13 Other Indications

Chapter 6. Global CAR-T Cell Therapy Market, by Target Antigen

• 6.1 Introduction
• 6.2 CD19/CD22
• 6.3 BCMA
• 6.4 Others

Chapter 7. CAR-T Cell Therapy Market Assessment by Geography

• 7.1 Introduction
• 7.2 CAR-T Cell Therapy Market - North America
  • 7.2.1 CAR-T Cell Therapy Market - U.S.
  • 7.2.2 CAR-T Cell Therapy Market - Canada
• 7.3 CAR-T Cell Therapy Market - Europe
  • 7.3.1 CAR-T Cell Therapy Market - Germany
  • 7.3.2 CAR-T Cell Therapy Market - UK
  • 7.3.3 CAR-T Cell Therapy Market - France
  • 7.3.4 CAR-T Cell Therapy Market - Italy
  • 7.3.5 CAR-T Cell Therapy Market - Spain
  • 7.3.6 CAR-T Cell Therapy Market - Netherlands
  • 7.3.7 CAR-T Cell Therapy Market - Austria
• 7.4 CAR-T Cell Therapy Market - Asia Pacific
  • 7.4.1 CAR-T Cell Therapy Market - China
  • 7.4.2 CAR-T Cell Therapy Market - India
  • 7.4.3 CAR-T Cell Therapy Market - Japan
  • 7.4.4 CAR-T Cell Therapy Market - South Korea
  • 7.4.5 CAR-T Cell Therapy Market - Australia
• 7.5 CAR-T Cell Therapy Market - Latin America
  • 7.5.1 CAR-T Cell Therapy Market - Brazil
  • 7.5.2 CAR-T Cell Therapy Market - Mexico
• 7.6 CAR-T Cell Therapy Market - Middle East & Africa
  • 7.6.1 CAR-T Cell Therapy Market - Saudi Arabia
  • 7.6.2 CAR-T Cell Therapy Market - UAE

Chapter 8. Competitive Landscape

• 8.1 Product Launch and Acquisition Are the Best Adopted Strategy by the Companies
• 8.2 Product Launch
• 8.3 Partnerships/Collaborations/Agreements/Exhibitions

Chapter 9. Company Profiles

• 9.1 Bluebird Bio
  • 9.1.1 Company Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Benchmarking
  • 9.1.4 Recent Development
• 9.2 Celgene Corporation
  • 9.2.1 Company Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Benchmarking
  • 9.2.4 Recent Development
• 9.3 Gilead Sciences, Inc.
  • 9.3.1 Company Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Benchmarking
  • 9.3.4 Recent Development
• 9.4 Cellectis
  • 9.4.1 Company Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Benchmarking
  • 9.4.4 Recent Development
• 9.5 Servier Laboratories
  • 9.5.1 Company Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Benchmarking
  • 9.5.4 Recent Development
• 9.6 Pfizer Inc.
  • 9.6.1 Company Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Benchmarking
  • 9.6.4 Recent Development
• 9.7 Merck KGaA
  • 9.7.1 Company Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Benchmarking
  • 9.7.4 Recent Development
• 9.8 Amgen Inc.
  • 9.8.1 Company Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Benchmarking
  • 9.8.4 Recent Development
• 9.9 Intellia Therapeutics
  • 9.9.1 Company Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Benchmarking
  • 9.9.4 Recent Development
• 9.10 Novartis International AG
  • 9.10.1 Company Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Benchmarking
  • 9.10.4 Recent Development
• 9.11 Caribou Biosciences, Inc
  • 9.11.1 Company Overview
  • 9.11.2 Financial Performance
  • 9.11.3 Product Benchmarking
  • 9.11.4 Recent Development
• 9.12 Celyad
  • 9.12.1 Company Overview
  • 9.12.2 Financial Performance
  • 9.12.3 Product Benchmarking
  • 9.12.4 Recent Development
• 9.13 Bellicum Pharmaceuticals, Inc.
  • 9.13.1 Company Overview
  • 9.13.2 Financial Performance
  • 9.13.3 Product Benchmarking
  • 9.13.4 Recent Development
• 9.14 Noile-Immune Biotech
  • 9.14.1 Company Overview
  • 9.14.2 Product Benchmarking
  • 9.14.3 Recent Development
• 9.15 Nanjing Legend Biotechnology Co., Ltd.
  • 9.15.1 Company Overview
  • 9.15.2 Product Benchmarking
  • 9.15.3 Recent Development
• 9.16 Johnson & Johnson
  • 9.16.1 Company Overview
  • 9.16.2 Financial Performance
  • 9.16.3 Product Benchmarking
  • 9.16.4 Recent Development
• 9.17 Sangamo Therapeutics, Inc.
  • 9.17.1 Company Overview
  • 9.17.2 Financial Performance
  • 9.17.3 Product Benchmarking
  • 9.17.4 Recent Development